Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Connect with us:
Latest from Cleveland Clinic
Dr Kamath on the Rationale for Investigating Early-Onset vs Average-Onset PDAC
June 12, 2024
Video
Suneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.
Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC
June 10, 2024
Video
Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.
Dr Carraway on the Importance of NGS in Relapsed/Refractory AML
May 29, 2024
Video
Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
May 24, 2024
Article
James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.
Dr Jain on Unmet Needs in the Treatment of Low- and High-Risk MDS
April 25, 2024
Video
Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.
Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian Cancer
April 12, 2024
Video
Gabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
April 10, 2024
Article
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Dr Dima on Real-World Responses With Teclistamab in R/R Multiple Myeloma
April 05, 2024
Video
Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.
Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer
April 05, 2024
Article
Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.
Dr Olivares on the Use of Focal Therapy in Localized Prostate Cancer
March 26, 2024
Video
Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.
Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
March 25, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Ongoing Research Efforts in HER2+ Early Breast Cancer
March 25, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.
AE Management With Neratinib in HER2+ Early Breast Cancer
March 18, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Unmet Needs in HER2+ Early Breast Cancer
March 18, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.
Evolving and Current Standards of Care for HER2+ Early Breast Cancer
March 12, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Prognosis and Survival Outcomes for HER2+ Early Breast Cancer
March 12, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
Dr DeBernardo on the Use of Later-Line Maintenance Therapy in Ovarian Cancer
February 16, 2024
Video
Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.
Future Perspectives on the Treatment Landscape for CLL
February 16, 2024
Video
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Expert Insights into Investigation Therapies for CLL
February 16, 2024
Video
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Dr Dima on the Mechanism of Action of Teclistamab in Relapsed/Refractory Multiple Myeloma
February 09, 2024
Video
Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.